Quest Diagnostics Incorporated $DGX Stock Acquired by Wedbush Securities Inc.

Wedbush Securities Inc. increased its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 280.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,465 shares of the medical research company’s stock after purchasing an additional 4,028 shares during the quarter. Wedbush Securities Inc.’s holdings in Quest Diagnostics were worth $1,274,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of DGX. Concurrent Investment Advisors LLC raised its position in Quest Diagnostics by 1.2% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 5,183 shares of the medical research company’s stock worth $1,099,000 after purchasing an additional 62 shares during the last quarter. SBI Securities Co. Ltd. lifted its holdings in Quest Diagnostics by 17.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 441 shares of the medical research company’s stock worth $112,000 after buying an additional 67 shares in the last quarter. PFG Private Wealth Management LLC lifted its holdings in Quest Diagnostics by 5.1% during the 2nd quarter. PFG Private Wealth Management LLC now owns 1,453 shares of the medical research company’s stock worth $308,000 after buying an additional 71 shares in the last quarter. Koshinski Asset Management Inc. lifted its holdings in Quest Diagnostics by 4.2% during the 1st quarter. Koshinski Asset Management Inc. now owns 2,062 shares of the medical research company’s stock worth $404,000 after buying an additional 84 shares in the last quarter. Finally, Wedmont Private Capital boosted its position in Quest Diagnostics by 2.8% in the 2nd quarter. Wedmont Private Capital now owns 3,120 shares of the medical research company’s stock valued at $647,000 after buying an additional 86 shares during the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on DGX. UBS Group reiterated a “neutral” rating and issued a $250.00 price objective on shares of Quest Diagnostics in a research report on Monday, October 19th. Barclays boosted their target price on Quest Diagnostics from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Robert W. Baird set a $262.00 price target on Quest Diagnostics in a research note on Friday. JPMorgan Chase & Co. raised their price target on Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a report on Tuesday, July 28th. Finally, Argus set a $260.00 price objective on Quest Diagnostics in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $244.27.

Insider Buying and Selling

In related news, SVP Michael Prevoznik sold 22,677 shares of Quest Diagnostics stock in a transaction on Friday, August 28th. The stock was sold at an average price of $243.11, for a total transaction of $5,513,005.47. Following the completion of the sale, the senior vice president directly owned 37,557 shares of the company’s stock, valued at $9,130,482.27. The trade was a 37.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. Davis sold 10,000 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $242.72, for a total value of $2,427,200.00. Following the completion of the sale, the chief executive officer owned 122,423 shares of the company’s stock, valued at $29,714,510.56. This represents a 7.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 34,277 shares of company stock valued at $8,316,493 over the last three months. Company insiders own 0.88% of the company’s stock.

Quest Diagnostics News Roundup

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Third-quarter results beat estimates: Quest reported adjusted EPS of $3.00 versus the $2.87 consensus and revenue of $3.10 billion versus expectations of $3.05 billion. Revenue increased 10% year over year, while adjusted EPS rose 15.4%, reflecting stronger testing demand and margin improvement. Quest Diagnostics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised: Quest now expects 2026 revenue of $12.065 billion to $12.105 billion and adjusted EPS of $11.25 to $11.35, above consensus estimates of approximately $12.0 billion and $11.19, respectively. Organic requisition volume rose 14.4% in the quarter, and consumer-health revenue is expected to grow more than 30% for the year. Quest Diagnostics Earnings Takeaways
• Positive Sentiment: Valuation and momentum remain supportive: Coverage characterized DGX as potentially undervalued following the guidance increase, while Zacks highlighted the company’s long-term momentum profile. Quest Diagnostics Could Be Undervalued
• Neutral Sentiment: Deutsche Bank raised its price target to $245 from $232 but maintained a Hold rating, indicating improved expectations without a clear bullish endorsement. Deutsche Bank Adjusts Quest Diagnostics Price Target
• Negative Sentiment: Patient-data breach creates a major overhang: Quest disclosed unauthorized access to its Quanum Lab Services Manager, a system used to order tests and access results. The company confirmed that personal and health information was compromised, potentially exposing it to regulatory scrutiny, litigation, remediation costs, and reputational damage. Quest Diagnostics Patient Data Breach

Quest Diagnostics Price Performance

Shares of DGX stock opened at $241.49 on Monday. The firm’s 50 day moving average price is $237.67 and its two-hundred day moving average price is $216.94. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.58 and a current ratio of 1.70. Quest Diagnostics Incorporated has a 52-week low of $171.18 and a 52-week high of $248.84. The stock has a market cap of $26.65 billion, a PE ratio of 24.05, a PEG ratio of 2.17 and a beta of 0.54.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Thursday, October 22nd. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.87 by $0.13. The company had revenue of $3.10 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Quest Diagnostics had a net margin of 9.53% and a return on equity of 16.21%. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.60 EPS. As a group, analysts forecast that Quest Diagnostics Incorporated will post 11.27 EPS for the current year.

Quest Diagnostics Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th were given a $0.86 dividend. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. The ex-dividend date was Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio (DPR) is currently 34.26%.

Quest Diagnostics Profile

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.